Contact Us marketing@medicilon.com
Medicilon Logo
|
search icon search icon contact icon menu icon
Medicilon Logo
|
search icon close search icon contact icon menu icon
Message
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Medicilon Events
News and Events

Medicilon Events

Hot information:
Medicilon Appoints Dr. Liu Jian as President of Drug Discovery Division| Medicilon and Wuhan biolake successfully organized a biopharmaceutical salon| Medicilon FTE services & FFS services - flexible and efficient cooperation model
Oct 08,2024
Entering the ranks of international authoritative testing! Medicilon has been awarded the CNAS accreditation certificate.
Recently, Medicilon successfully passed the rigorous qualification review and assessment by the China National Accreditation Service for Conformity Assessment (CNAS).
More
Entering the ranks of international authoritative testing! Medicilon has been awarded the CNAS accreditation certificate.
Sep 13,2024
Preclinical + Clinical Comprehensive Empowerment for Anti-Tumor Drug Development! Medicilon has reached a strategic collaboration with Shanghai GoBroad Cancer Hospital and Start Shanghai Company
Recently, Shanghai Medicilon Inc. (Medicilon) officially signed a tripartite strategic collaboration framework agreement with China Pharmaceutical University Affiliated Shanghai GoBroad Cancer Hospital (Shanghai GoBroad) and Start Shanghai Company (Start Shanghai).
More
Preclinical + Clinical Comprehensive Empowerment for Anti-Tumor Drug Development! Medicilon has reached a strategic collaboration with Shanghai GoBroad Cancer Hospital and Start Shanghai Company
Sep 13,2024
Medicilon Non-tumor Pharmacology Service Platform
Medicilon boasts 260+ evaluation models for non-tumor diseases, covering the inflammatory & immune diseases, CNS diseases, digestive diseases, , Metabolic diseases, cardiovascular diseases and other diseases.
More
Medicilon Non-tumor Pharmacology Service Platform
Aug 29,2024
Medicilon Expands Global Presence with Official Opening of Second R&D Center in Massachusetts
In August 2024, Medicilon USA Corp (Medicilon)officially commenced operations at its second R&D center in Massachusetts, USA.
More
Medicilon Expands Global Presence with Official Opening of Second R&D Center in Massachusetts
Aug 06,2024
Medicilon's Antibody Technology Targeting Nectin-4 has been Awarded a National Invention Patent
Recently, Medicilon has successfully obtained an invention patent from the National Intellectual Property Administration for its self-developed project titled "Antibodies Targeting Nectin-4 and Their Various Applications"!
More
Medicilon's Antibody Technology Targeting Nectin-4 has been Awarded a National Invention Patent
Jul 31,2024
Medicilon and Hengrui Pharma Deepen Strategic Collaboration to Support Innovation in ADCs, Small Nucleic Acids, and CGT Drugs
On July 17th, Shanghai Medicilon Inc. ("Medicilon") and Jiangsu Hengrui Pharmaceuticals Co., Ltd. ("Hengrui Pharma") reached a strategic collaboration agreement.
More
Medicilon and Hengrui Pharma Deepen Strategic Collaboration to Support Innovation in ADCs, Small Nucleic Acids, and CGT Drugs
Jul 26,2024
2024 (The 7th) Toxicity Testing Alternatives and Translational Toxicology International Conference was successfully held in Nanchang
From July 3 to 6, 2024, 2024 (The 7th) Toxicity Testing Alternatives and Translational Toxicology International Conference was successfully held in Nanchang, Jiangxi.
More
2024 (The 7th) Toxicity Testing Alternatives and Translational Toxicology International Conference was successfully held in Nanchang
Jul 26,2024
Recognition for Service! Medicilon Receives the "Excellent Service Award" from Allorion Therapeutics
On July 17, Dr. Yaoyu Chen, Co-founder of Allorion Therapeutics (Allorion), and Dr. Jiaqi Liang, Head of Biology, visited Medicilon's Chuansha campus in Shanghai to present the "Excellent Service Award" to Medicilon's pharmacology department.
More
Recognition for Service! Medicilon Receives the "Excellent Service Award" from Allorion Therapeutics
Jul 22,2024
The Shanghai Overseas Returned Scholars Association invites the Dutch PhD delegation to visit Medicilon, exploring paths for innovative development together
On July 4th, the Shanghai Overseas Returned Scholars Association invited the Dutch PhD delegation to visit the Chuansha campus of Shanghai Medicilon Inc. (Medicilon) and held discussions with Medicilon's Founder and CEO, Chunlin Chen, among others.
More
The Shanghai Overseas Returned Scholars Association invites the Dutch PhD delegation to visit Medicilon, exploring paths for innovative development together
Jul 22,2024
5th consecutive win! Medicilon once again made the list of "Top 20 Chinese R&D CRO Enterprises in 2024"
Medicilon stood out among hundreds of pharmaceutical enterprises and was honored with the "Top 20 Chinese R&D CRO Enterprises in 2024" award.
More
5th consecutive win! Medicilon once again made the list of "Top 20 Chinese R&D CRO Enterprises in 2024"
Jul 22,2024
Great news! Medicilon Analytical Testing Center has passed the CNAS on-site assessment!
Recently, the Analytical Testing Center of Shanghai Medicilon Inc. (Medicilon) successfully passed the on-site assessment by the China National Accreditation Service for Conformity Assessment (CNAS).
More
Great news! Medicilon Analytical Testing Center has passed the CNAS on-site assessment!
Jul 10,2024
Medicilon Preclinical Research and Hetuo Innovation are joining hands to co-create and innovate in drug development
Medicilon announced that its wholly-owned subsidiary, Medicilon Preclinical Research (MRP), has officially signed a collaboration agreement with Hetuo Innovation (Hetuo) in the fields of neurological disorders, ophthalmic diseases, and cardiovascular system drugs​.
More
Medicilon Preclinical Research and Hetuo Innovation are joining hands to co-create and innovate in drug development